Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects

Lignende værker

• In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043
  af: Zhou, Nannan, et al.
  Udgivet: (2011)
• In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068
  af: Nowicka-Sans, Beata, et al.
  Udgivet: (2012)
• Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects
  af: Zhu, Li, et al.
  Udgivet: (2015)
• Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529
  af: Landry, Ishani, et al.
  Udgivet: (2016)
• Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors
  af: Li, Zhufang, et al.
  Udgivet: (2013)